Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Open Access
- 14 March 2025
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 202, 108487
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Foundation for the National Institutes of Health
This publication has 20 references indexed in Scilit:
- Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3ANature Communications, 2023
- APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinomaLung Cancer, 2022
- Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinomaCancer Letters, 2021
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA SequencingCell, 2020
- Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9–13European Urology, 2020
- APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinomaOncogene, 2019
- Universal Patterns of Selection in Cancer and Somatic TissuesCell, 2018
- Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12COncogene, 2018
- The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillanceBBA Clinical, 2016
- Resisting Resistance: Targeted Therapies in Lung CancerTrends in Cancer, 2016